Johnson & Johnson MedTech has launched the Collaborative Outcomes Registry for Evidence in Ventricular Arrhythmias (CORE-VA), a new registry designed to collect data on the treatment of ventricular arrhythmias, including ventricular tachycardia (VT). The initiative was announced in partnership with Heart Rhythm Clinical and Research Solutions, LLC., at the International Symposium on Ventricular Arrhythmias in Philadelphia.
CORE-VA is a prospective, multicenter registry intended to gather information about current clinical practices, technologies, and patient outcomes related to ventricular arrhythmia ablation. The registry aims to become the largest database of its kind for mapping and ablation procedures in this field.
Francis E. Marchlinski, M.D., Director of Electrophysiology at the University of Pennsylvania Health Care System and Co-Chair of the CORE-VA Steering Committee, stated: “Real-world standard-of-care registries are essential for refining techniques, guiding training and expanding patient access. CORE-VA could illuminate how we can simplify procedures, further identify and avoid risks, and improve access and outcomes for ventricular arrhythmia patients.”
Ventricular tachycardia is a fast heart rhythm that originates in the lower chambers of the heart. Together with ventricular fibrillation, it accounts for most sudden cardiac deaths in the United States, causing approximately 300,000 deaths annually (https://www.ncbi.nlm.nih.gov/books/NBK532954/). Because VT ablation is complex, it is typically performed by specialized electrophysiologists using advanced methods (https://www.ncbi.nlm.nih.gov/books/NBK532954/).
Jennifer Currin Ph.D., Vice President of Scientific Affairs for Electrophysiology at Johnson & Johnson MedTech, said: “CORE-VA is another example of Johnson & Johnson’s commitment to building rigorous clinical and scientific evidence that shapes the future of arrhythmia care. As new technologies are introduced and adopted into clinical practice, this registry will enable us to rapidly collect and analyze real-world data, helping to benchmark outcomes against existing technologies and guide best practices. The insights gained through this collaborative effort have the potential to inform clinical standards, training initiatives and future advancements in this complex arrythmia field.”
According to Johnson & Johnson MedTech, their cardiovascular portfolio offers healthcare professionals tools for advanced mapping and navigation as well as miniaturized technology for precise ablation. The company states it holds a leading position globally in heart recovery and circulatory restoration solutions.
The company cautioned that forward-looking statements in this announcement are based on current expectations but may be affected by risks such as competition or changes in healthcare policy. More information can be found through their official filings at www.sec.gov or www.jnj.com.
Dr. Marchlinski serves as a consultant for Johnson & Johnson but was not compensated for this announcement.